• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于治疗帕金森病的左旋多巴和卡比多巴药物原料的可扩展不对称合成。

Scalable Asymmetric Syntheses of Foslevodopa and Foscarbidopa Drug Substances for the Treatment of Parkinson's Disease.

作者信息

Huters Alexander D, Stambuli James, Klix Russell C, Matulenko Mark A, Chan Vincent S, Simanis Justin, Hill David R, Reddy Rajarathnam E, Towne Timothy B, Bellettini John R, Kotecki Brian J, Cardinal-David Benoit, Ji Jianguo, Voight Eric A, Shou Minshan, Balaraman Selvakumar, Ashok Abhishek, Ghosh Soma

机构信息

Anthem Biosciences, No. 49 Canara Bank Road, Bommasandra Industrial Area, Bangalore 560 099, Karnataka, India.

出版信息

J Org Chem. 2022 Feb 18;87(4):1986-1995. doi: 10.1021/acs.joc.1c00905. Epub 2021 Jul 19.

DOI:10.1021/acs.joc.1c00905
PMID:34280307
Abstract

Foslevodopa (FLD, levodopa 4'-monophosphate, ) and foscarbidopa (FCD, carbidopa 4'-monophosphate, ) were identified as water-soluble prodrugs of levodopa (LD, ) and carbidopa (CD, ), respectively, which are useful for the treatment of Parkinson's disease. Herein, we describe asymmetric syntheses of FLD () and FCD () drug substances and their manufacture at pilot scale. The synthesis of FLD () employs a Horner-Wadsworth-Emmons olefination reaction followed by enantioselective hydrogenation of the double bond as key steps to introduce the α-amino acid moiety with the desired stereochemistry. The synthesis of FCD () features a Mizoroki-Heck reaction followed by enantioselective hydrazination to install the quaternary chiral center bearing a hydrazine moiety.

摘要

福司左旋多巴(FLD,左旋多巴4'-单磷酸酯)和福司卡比多巴(FCD,卡比多巴4'-单磷酸酯)分别被鉴定为左旋多巴(LD)和卡比多巴(CD)的水溶性前药,它们可用于治疗帕金森病。在此,我们描述了FLD()和FCD()原料药的不对称合成及其中试规模生产。FLD()的合成采用霍纳尔-沃兹沃思-埃蒙斯烯烃化反应,随后对双键进行对映选择性氢化作为关键步骤,以引入具有所需立体化学的α-氨基酸部分。FCD()的合成特点是米佐罗基-赫克反应,随后进行对映选择性肼化以安装带有肼部分的季碳手性中心。

相似文献

1
Scalable Asymmetric Syntheses of Foslevodopa and Foscarbidopa Drug Substances for the Treatment of Parkinson's Disease.用于治疗帕金森病的左旋多巴和卡比多巴药物原料的可扩展不对称合成。
J Org Chem. 2022 Feb 18;87(4):1986-1995. doi: 10.1021/acs.joc.1c00905. Epub 2021 Jul 19.
2
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.晚期帕金森病患者连续皮下注射左多巴-卡比多巴的安全性和有效性:一项随机、双盲、阳性对照、3 期临床试验。
Lancet Neurol. 2022 Dec;21(12):1099-1109. doi: 10.1016/S1474-4422(22)00400-8.
3
Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion.福司列弗多巴/福卡比多巴经皮下输注后具有良好的耐受性,并能维持稳定的左旋多巴和卡比多巴暴露量。
J Parkinsons Dis. 2021;11(4):1695-1702. doi: 10.3233/JPD-212813.
4
Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease.福司列弗多巴/福卡多巴:帕金森病的一种新皮下治疗方法。
Ann Neurol. 2021 Jul;90(1):52-61. doi: 10.1002/ana.26073. Epub 2021 May 4.
5
Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum.福司列弗多巴/卡比多巴皮下输注与左旋多巴-卡比多巴肠凝胶输送至空肠的暴露量等效。
Parkinsonism Relat Disord. 2022 Apr;97:68-72. doi: 10.1016/j.parkreldis.2022.03.012. Epub 2022 Mar 22.
6
Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC-HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel.采用 LC-HRMS 对健康人体参与者血浆中的 foslevodopa/foscarbidopa 进行代谢物分析,结果表明与给予左旋多巴/卡比多巴肠凝胶相比无明显差异。
Pharmacol Res Perspect. 2024 Apr;12(2):e1190. doi: 10.1002/prp2.1190.
7
Continuous Subcutaneous Foslevodopa-Foscarbidopa in Parkinson's Disease: A Mini-Review of Current Scope and Future Outlook.帕金森病中持续皮下注射左多巴-卡比多巴:当前范围和未来展望的小型综述。
Mov Disord Clin Pract. 2024 Oct;11(10):1188-1194. doi: 10.1002/mdc3.14161. Epub 2024 Jul 11.
8
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.帕金森病患者皮下持续输注左旋多巴/卡比多巴:一项为期12个月的单臂、开放标签3期研究的安全性和有效性结果
Neurol Ther. 2023 Dec;12(6):1937-1958. doi: 10.1007/s40120-023-00533-1. Epub 2023 Aug 26.
9
Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa.福司列弗多巴/卡比多巴改善睡眠与提高生活质量和运动症状相关。
Mov Disord Clin Pract. 2024 Jul;11(7):861-866. doi: 10.1002/mdc3.14018. Epub 2024 Mar 11.
10
Comparability of Foslevodopa/Foscarbidopa Pharmacokinetics in Healthy Asian and White Participants.福沙左旋多巴/福沙卡比多巴在健康亚洲和白人受试者中药代动力学的可比性
Clin Pharmacol Drug Dev. 2023 Apr;12(4):407-415. doi: 10.1002/cpdd.1201. Epub 2022 Nov 16.

引用本文的文献

1
Mild and Chemoselective Triethylsilane-Mediated Debenzylation for Phosphate Synthesis.用于磷酸酯合成的温和且化学选择性的三乙基硅烷介导的脱苄基反应
Org Lett. 2025 Jan 10;27(1):246-251. doi: 10.1021/acs.orglett.4c04258. Epub 2024 Dec 24.
2
Continuous Subcutaneous Foslevodopa-Foscarbidopa in Parkinson's Disease: A Mini-Review of Current Scope and Future Outlook.帕金森病中持续皮下注射左多巴-卡比多巴:当前范围和未来展望的小型综述。
Mov Disord Clin Pract. 2024 Oct;11(10):1188-1194. doi: 10.1002/mdc3.14161. Epub 2024 Jul 11.
3
Enantioselective organocatalytic strategies to access noncanonical α-amino acids.
用于合成非天然α-氨基酸的对映选择性有机催化策略。
Chem Sci. 2024 Mar 25;15(16):5832-5868. doi: 10.1039/d4sc01081g. eCollection 2024 Apr 24.
4
Catalytic Asymmetric α-Functionalization of α-Branched Aldehydes.α-支链醛的手性催化不对称α-官能化。
Molecules. 2023 Mar 16;28(6):2694. doi: 10.3390/molecules28062694.
5
Fueling the Pipeline via Innovations in Organic Synthesis.通过有机合成创新为人才培养输送力量。
ACS Med Chem Lett. 2021 Aug 27;12(9):1365-1373. doi: 10.1021/acsmedchemlett.1c00351. eCollection 2021 Sep 9.